Expanding diabetes diagnostics with a fully automated CLIA solution

BioVendor brings a unique diagnostic advantage with a fully automated CLIA panel combining functional markers C-peptide and Insulin with autoimmune markers GAD65 and IA-2, supporting faster and more accurate diabetes differentiation.
BioVendor is introducing a comprehensive diabetes panel that integrates both functional and autoimmune markers into a single, fully automated CLIA workflow. This solution provides a unique market advantage by offering GAD65 and IA-2 markers in a CLIA format, enabling more precise and earlier differentiation between Type 1, Type 2, and LADA diabetes. By replacing traditional ELISA and RIA methods, the platform significantly enhances laboratory efficiency and safety through faster processing, higher throughput, and the elimination of radioactive materials.